MENU

REGN Stock Regeneron Pharmaceuticals (REGN, $701.85) entered a bearish trend. Expect a Downtrend continuation

A.I.dvisor
at Tickeron.com
Loading...
REGN - Regeneron Pharmaceuticals
Bearish Trend Signal
Bearish Trend
Odds of DOWN Trend
Tickeron

Loading...

Price: $701.85
Daily change: -$6.4 (-0.9%)
Daily volume: 1.9M
Capitalization: $77.1B
Industry: Biotechnology
Regeneron Pharmaceuticals (REGN, $701.85) is predicted by A.I.dvisor to decline by to $673.78 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended down during the month, the odds of a Downtrend continuation are

REGN's Indicator enters downward trend

The Aroon Indicator for REGN entered a downward trend on December 20, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 174 similar instances where the Aroon Indicator formed such a pattern. In of the 174 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on REGN as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

REGN broke above its upper Bollinger Band on December 06, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on November 25, 2024. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.630) is normal, around the industry mean (14.529). P/E Ratio (17.360) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (1.044) is also within normal values, averaging (1.739). REGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (5.834) is also within normal values, averaging (255.281).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medicines for the treatment of serious medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
777 Old Saw Mill River Road
Phone
+1 914 847-7000
Employees
13450
Web
https://www.regeneron.com